Caloric Restriction Before Surgery in Treating Patients With Endometrial, Prostate, or Breast Cancer

PRIMARY OBJECTIVES:

1) Investigate if caloric restriction will change serum micro ribonucleic acid (RNA) 21
(miR-21) expression in patients with prostate, endometrial or breast cancer.

SECONDARY OBJECTIVES:

1. Investigate measurable changes induced by caloric restriction on both patient (host) and
tumor characteristics from caloric restriction.

2. Investigate the adherence of the patient to the diet.

4) Weight, height, and body composition will be assessed via BodyMetrix. BodyMetrix uses
ultrasound technology to measure subcutaneous fat.

5) Patients will have psycho-social evaluation using the Functional Assessment of Cancer
Therapy-Prostate (FACT-P) test (prostate cancer), FACT-Breast (B) test (breast cancer), or
the FACT-Endometrial Cancer (En) test (endometrial cancer) and the Patient Reported Outcomes
Measurement Information System (PROMIS) cancer fatigue short form at baseline, midway through
diet, and at the conclusion of the diet.

6) Patient's nutritional status (Mini Nutritional Assessment [MNA] form) will be assessed,
and their caloric needs will be calculated.

7) Local recurrence, progression free survival, distant metastases and overall survival will
be assessed.

Inclusion Criteria:

1. Histological documentation of cancer of the endometrium, prostate or breast.

2. Candidate for definitive cancer surgery as determined by treating physician

3. The ability for the definitive cancer surgery to be scheduled within 4-12 weeks post
initiation of dietary intervention as determined by the enrolling physician (not from
diagnosis - but from start of diet).

4. No other malignancy within the past 6 months unless it was a non-melanomatous skin
lesion

5. BMI ≥21

6. ECOG Performance Status of 2 or less

7. Patient must not be on anti-retrovirals since they may alter patient metabolism

Exclusion Criteria:

1. Patient is not a candidate for definitive cancer surgery

2. Definitive cancer surgery can not be performed within 4-12 weeks post study enrollment
as determined by the enrolling physician.

3. Body Mass Index < 21

4. Another malignancy within the past 6 months that was not a non-melanomatous skin
lesion

5. ECOG Performance Status >2

6. Patient on anti-retrovirals since they may alter patient metabolism